GLP-1 drugs, the treatment class popularized by Eli Lilly (LLY) and Novo Nordisk (NVO), could generate $150B in global sales ...

Data readout from the maintenance dosing study of VK2735, the company’s investigational obesity candidate, is expected in the ...

While those timelines might not seem exciting, investors should note that Viking is due to release results from an extremely ...

Fintel reports that on May 28, 2026, Lake Street initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Buy recommendation. Analyst Price Forecast Suggests 203.25% Upside As of May 14, 2026, ...

Investors have increasingly poured capital into pharmaceutical and biotech companies developing obesity treatments in recent ...

From late 2023 to early 2024, Viking Therapeutics (NASDAQ: VKTX) took off like a rocket, as it seemed that the clinical-stage ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Most investors currently see the glass on this stock as being half-empty. Analysts, however, still view the glass as at least half-full.

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 20 Stocks Jim Cramer Wanted You To Sell & Immediately Get Out Of. Viking Therapeutics Inc. (NASDAQ:VKTX) is a biotechnology company developing ...

Viking Therapeutics Inc. (NASDAQ:VKTX) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. Viking Therapeutics Inc. (NASDAQ:VKTX) is a biotechnology company developing treatments that ...